Ab Initio Biotherapeutics Overview

  • Founded
  • 2015
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $12M
Latest Deal Amount

Ab Initio Biotherapeutics General Information


Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-access cellular targets. The company's platform allows for targeting multi-transmembrane and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders, enabling doctors to optimize the solubility and stability of drugs.

Contact Information

Ownership Status
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 280 Utah Avenue
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ab Initio Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Jul-2019 $12M 000 0000 Completed Generating Revenue
3. Corporate 13-Dec-2016 000 Completed Startup
2. Angel (individual) $2M $2M Completed Startup
1. Accelerator/Incubator 03-Mar-2015 Completed Startup
To view Ab Initio Biotherapeutics’s complete valuation and funding history, request access »

Ab Initio Biotherapeutics Executive Team (6)

Name Title Board Seat Contact Info
Robert Booth Ph.D Co-Founder & Executive Chairman
You’re viewing 1 of 6 executive team members. Get the full list »

Ab Initio Biotherapeutics Board Members (1)

Name Representing Role Since
Robert Booth Ph.D Self Co-Founder & Executive Chairman 000 0000
To view Ab Initio Biotherapeutics’s complete board members history, request access »

Ab Initio Biotherapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator 000 0000 000000 0
Pfizer Corporation Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
To view Ab Initio Biotherapeutics’s complete investors history, request access »